Total raised
—
Stage
Acquired
Founded
1959
Headcount
1,344
HQ
Haifa
Sector
Health Tech & Life Sciences
About
Taro Pharmaceutical Industries is a research-based international pharmaceutical company manufacturing topical dermatological products and developing a line of solid drugs in cardiology and neurology. Taro synthesizes the active ingredients used in many of its key products. This vertical integration gives Taro control over the manufacturing and quality-control process from the active ingredients to the finished product and provides the company with a competitive advantage in the availability of quality raw materials, the reliability of supply, and the cost of active pharmaceutical ingredients.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Taro Pharmaceutical Industries acquired and by whom?
- Taro Pharmaceutical Industries was acquired by Sun Pharma in June 2024.
- What was the acquisition amount for Taro Pharmaceutical Industries by Sun Pharma?
- The acquisition of Taro Pharmaceutical Industries by Sun Pharma in June 2024 was for $348 million.
- When did Taro Pharmaceutical Industries go public?
- Taro Pharmaceutical Industries had its IPO in March 2012 on the NYSE under the ticker TARO.
- What is the primary focus of Taro Pharmaceutical Industries' product manufacturing?
- Taro Pharmaceutical Industries primarily manufactures topical dermatological products and develops solid drugs in cardiology and neurology.
- Where is Taro Pharmaceutical Industries headquartered?
- Taro Pharmaceutical Industries is headquartered in Haifa, Israel, with additional offices in Hawthorne, NY, USA, and Brampton, ON, Canada.
- What was a significant regulatory approval for Taro Pharmaceutical Industries' product Pliaglis?
- In December 2018, the U.S. FDA approved the removal of the "Not for Home Use" label restriction for Taro Pharmaceutical Industries' product Pliaglis®.
- What was a notable partnership for Taro Pharmaceutical Industries in Israel?
- In June 2020, NTC granted Taro Pharmaceutical Industries license and distribution rights in Israel for its fixed combination of an ophthalmic quinolone antibiotic with an anti-inflammatory steroid.
- What was the market capitalization of Taro Pharmaceutical Industries as of November 2023?
- As of November 1, 2023, Taro Pharmaceutical Industries had a market capitalization of $1,277,876,352.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Materials & SubstancesRaw Materials
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business model
B2B
Highlights
1 Patents
Tags
pharmaceuticalsmanufacturinghealthcare-providerstopical-treatmentcardiovascularoral-drugspediatricsdrug-discoveryhospitalsdermatologyanti-inflammatorytreatments